HC Wainwright Has Bullish Estimate for DTIL FY2027 Earnings

Precision BioSciences, Inc. (NASDAQ:DTIL) – Research analysts at HC Wainwright lifted their FY2027 EPS estimates for Precision BioSciences in a research note issued on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.20 per share for the year, up from their previous forecast of $0.19. HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is $0.82 per share. HC Wainwright also issued estimates for Precision BioSciences’ FY2028 earnings at $0.40 EPS.

Precision BioSciences Stock Up 0.2 %

Shares of DTIL stock opened at $8.42 on Wednesday. Precision BioSciences has a twelve month low of $7.97 and a twelve month high of $19.43. The business has a fifty day simple moving average of $9.27 and a 200 day simple moving average of $10.04. The company has a market cap of $60.88 million, a P/E ratio of 140.36 and a beta of 1.71.

Institutional Investors Weigh In On Precision BioSciences

An institutional investor recently bought a new position in Precision BioSciences stock. Janus Henderson Group PLC acquired a new stake in Precision BioSciences, Inc. (NASDAQ:DTIL) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned about 8.29% of Precision BioSciences at the end of the most recent reporting period. 37.99% of the stock is currently owned by institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.